PMID- 29628511
OWN - NLM
STAT- MEDLINE
DCOM- 20181016
LR  - 20211204
IS  - 1698-6997 (Electronic)
IS  - 1139-6121 (Linking)
VI  - 20
IP  - 1
DP  - 2018 Jan-Mar
TI  - Dolutegravir Neuropsychiatric Adverse Events: Specific Drug Effect or Class 
      Effect.
PG  - 14-26
AB  - Integrase strand transfer inhibitors (INSTIs) are a newer class of antiretroviral 
      treatment for HIV-infected patient. INSTIs currently available for use are 
      raltegravir, elvitegravir, dolutegravir (DTG), and bictegravir. Clinical studies 
      using INSTIs have demonstrated an 80-90% efficiency in treating HIV-positive 
      antiretroviral therapy - naive patients. They are recommended by internatioal 
      guidelines as the preferred agents for the first-line regimen. INSTIs have also 
      been demonstrated as safe and tolerable. In clinical trials, the rate of adverse 
      events (AEs) such as neuropsychiatric AEs (NPSAEs) leading to discontinuation is 
      very low. However, recent published cohort studies show growing concerns on DTG 
      induced NPSAEs. In this paper, we will review available evidence about DTG - 
      NPSAEs and analyze whether the backbone (abacavir or tenofovir) matters as well 
      as discussing the possible mechanism behind this toxicity.
FAU - Yombi, Jean Cyr
AU  - Yombi JC
AD  - Department of Internal Medicine and Infectious Diseases, AIDS Reference Centre, 
      Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Spain
TA  - AIDS Rev
JT  - AIDS reviews
JID - 101134876
RN  - 0 (Amides)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HIV Integrase Inhibitors)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Heterocyclic Compounds, 4 or More Rings)
RN  - 0 (Oxazines)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - 0 (Quinolones)
RN  - 43Y000U234 (Raltegravir Potassium)
RN  - 4GDQ854U53 (elvitegravir)
RN  - 8GB79LOJ07 (bictegravir)
RN  - DKO1W9H7M1 (dolutegravir)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Amides
MH  - Dideoxynucleosides/adverse effects
MH  - HIV Integrase Inhibitors/adverse effects
MH  - Heterocyclic Compounds, 3-Ring/*adverse effects
MH  - Heterocyclic Compounds, 4 or More Rings/adverse effects
MH  - Humans
MH  - Neuropsychiatry
MH  - Oxazines
MH  - Piperazines
MH  - Pyridones
MH  - Quinolones/adverse effects
MH  - Raltegravir Potassium/adverse effects
EDAT- 2018/04/10 06:00
MHDA- 2018/10/17 06:00
CRDT- 2018/04/10 06:00
PHST- 2018/04/10 06:00 [entrez]
PHST- 2018/04/10 06:00 [pubmed]
PHST- 2018/10/17 06:00 [medline]
PST - ppublish
SO  - AIDS Rev. 2018 Jan-Mar;20(1):14-26.